• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses Show


Starting treatment with rivipansel (GMI-1070) shortly after vaso-occlusive crisis (VOC) onset significantly shortened hospital stays and the time to opioid discontinuation in children and adults with sickle cell disease (SCD), new analyses of the RESET clinical trial show.

The data further support “the potential benefits of treatment with rivipansel early in the course of VOC, as observed in sickle cell patients in the RESET trial — both in the total patient population as well as in the pediatric subgroup,” Helen Thackray, MD, said in a press release. Thackray is chief medical officer of GlycoMimetics, the therapy’s developer.

 

https://www.onescdvoice.com/wp-content/uploads/2020/12/Rivipansel-Treatment-for-VOCs.jpg